GO:0071353 cellular response to interleukin-4: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071353 (cellular response to interleukin-4) describes all changes in a cell's state or activity triggered by the cytokine interleukin-4 (IL-4).
• IL-4 signals through type I (IL-4Ralpha/gamma-c) and type II (IL-4Ralpha/IL-13Ralpha1) receptor complexes, activating JAK-STAT6 and IRS-PI3K pathways.
• The cellular response to IL-4 shapes Th2 differentiation, alternative macrophage activation, B-cell class switching, and fibroblast activation.
• IL-4 signaling in the tumor microenvironment drives immunotherapy resistance in ovarian cancer and pro-tumorigenic myelopoiesis in bone marrow.
• IL-4 contributes to atopic dermatitis skin barrier dysfunction and to drug resistance in hepatocellular carcinoma via macrophage extracellular traps.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal roles of IL-4 pathway genes in disease.
Description
The cellular response to interleukin-4 (GO:0071353) encompasses every process by which a cell changes its state or activity in response to the cytokine interleukin-4 (IL-4). IL-4 is a pleiotropic cytokine that acts on a wide range of cell types, including T cells, B cells, macrophages, fibroblasts, and epithelial cells, and it is central to type 2 immune responses. The official GO definition captures this breadth: any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-4 stimulus. Researchers study GO:0071353 because dysregulated IL-4 signaling is implicated in allergy, asthma, atopic dermatitis, and cancer progression. In tumors, IL-4 produced by cancer cells or bone marrow niches can promote immunotherapy resistance and pro-tumorigenic myelopoiesis. In chronic inflammatory skin diseases, IL-4 and IL-13 act on dermal fibroblasts to recruit T cells and impair the skin barrier. Understanding the molecular players and cellular outcomes of IL-4 stimulation is therefore critical for identifying therapeutic targets and biomarkers. This article provides a research-grade overview of GO:0071353, covering its definition, core mechanisms, key genes, disease links, and the CRISPR-based methods used to study it. All statements are grounded in published literature cited by number.
cellular response to interleukin-4 At A Glance
| GO ID | GO:0071353 |
|---|---|
| GO term | cellular response to interleukin-4 |
| Ontology | biological_process |
| Synonym | cellular response to IL-4 |
| Definition | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-4 stimulus. |
| Major function | Mediates cellular responses to IL-4, including JAK-STAT6 activation, Th2 differentiation, alternative macrophage activation, and B-cell class switching. |
| Key receptors | Type I IL-4 receptor (IL-4Ralpha/gamma-c) and type II IL-4 receptor (IL-4Ralpha/IL-13Ralpha1). |
| Major signaling pathways | JAK-STAT6, IRS-PI3K, and MAPK pathways. |
| Disease relevance | Allergy, atopic dermatitis, asthma, and cancer immunotherapy resistance. |
What Is GO:0071353?
GO:0071353 (cellular response to interleukin-4) is a biological process term defined as any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-4 stimulus. It includes signal transduction from IL-4 receptors, transcriptional reprogramming via STAT6, metabolic shifts, and functional outcomes such as cytokine secretion, proliferation, or differentiation. The synonym cellular response to IL-4 is used interchangeably.
Why Is cellular response to interleukin-4 Important in Cell Biology?
The cellular response to interleukin-4 is a central node in type 2 immunity and tissue homeostasis, and its dysregulation underlies major human diseases including atopic dermatitis, asthma, and cancer. In oncology, IL-4 signaling in the tumor microenvironment promotes immunotherapy resistance and pro-tumorigenic myelopoiesis, making it a high-priority target for combination therapies. In chronic inflammatory skin diseases, IL-4 and IL-13 act on fibroblasts and immune cells to drive barrier dysfunction and T-cell recruitment. Understanding GO:0071353 is therefore essential for both basic immunology and translational research.
• IL-4 signaling drives Th2 cell differentiation and type 2 immune responses.
• It promotes alternative (M2) macrophage activation, which is important in tissue repair and tumor progression.
• IL-4 induces B-cell class switching to IgE, a key process in allergic disease.
• In atopic dermatitis, IL-4 and IL-13 impair skin barrier function and promote T-cell recruitment.
• Ovarian cancer-derived IL-4 promotes immunotherapy resistance.
• An IL-4 signaling axis in bone marrow drives pro-tumorigenic myelopoiesis.
• IL-4 contributes to drug resistance in hepatocellular carcinoma via macrophage extracellular traps.
• Nasal mucosal fibroblasts produce IL-4 to induce Th2 responses.
• IL-4 modulates host defense against intracellular pathogens such as Listeria monocytogenes.
• CRISPR-based models are critical for dissecting causal roles of IL-4 pathway genes.
What Happens During cellular response to interleukin-4?
IL-4 Receptor Binding and Activation
In simple terms: IL-4 binds to receptors on the cell surface, switching them on.
The cellular response to IL-4 begins when IL-4 binds to either the type I receptor (IL-4Ralpha/gamma-c) or the type II receptor (IL-4Ralpha/IL-13Ralpha1). This binding induces receptor dimerization and activation of receptor-associated JAK kinases, which phosphorylate the IL-4Ralpha chain. The type II receptor is shared with IL-13 and is particularly important in non-hematopoietic cells such as fibroblasts and epithelial cells.
JAK-STAT6 Signaling
In simple terms: Activated JAKs phosphorylate STAT6, which moves to the nucleus and turns on IL-4 target genes.
Phosphorylated IL-4Ralpha recruits STAT6, which is then phosphorylated by JAKs, dimerizes, and translocates to the nucleus. In the nucleus, STAT6 binds to DNA and activates transcription of IL-4-responsive genes, including GATA3, SOCS1, and CCL26. This transcriptional program is a hallmark of the cellular response to IL-4 and drives Th2 differentiation and alternative macrophage activation.
IRS-PI3K and MAPK Pathways
In simple terms: IL-4 also activates additional signaling routes that control cell survival, metabolism, and proliferation.
In addition to STAT6, IL-4 receptor activation recruits insulin receptor substrate (IRS) proteins, leading to PI3K-AKT signaling. IL-4 can also activate MAPK pathways, which contribute to cell proliferation and survival. These pathways fine-tune the cellular response and are important in macrophages and fibroblasts.
Functional Outcomes: Differentiation, Secretion, and Tissue Remodeling
In simple terms: The signals change what the cell does: it may differentiate, secrete factors, or remodel tissue.
The cellular response to IL-4 results in diverse functional outcomes depending on cell type. In T cells, it promotes Th2 differentiation and secretion of IL-4, IL-5, and IL-13. In macrophages, it induces M2 polarization and secretion of pro-tumorigenic factors. In fibroblasts, IL-4 and IL-13 stimulate chemokine production that recruits T cells, contributing to atopic dermatitis. Nasal mucosal fibroblasts can also produce IL-4 to amplify Th2 responses.
Regulation and Feedback
In simple terms: The response is kept in check by feedback inhibitors and receptor regulation.
The cellular response to IL-4 is regulated by negative feedback mechanisms, including SOCS proteins that inhibit JAK-STAT signaling. Receptor internalization and degradation also limit the duration of signaling. Dysregulation of these checkpoints can lead to sustained IL-4 signaling, which is associated with chronic inflammation and cancer.
Key Genes Involved in GO:0071353 cellular response to interleukin-4
The following genes are central to the cellular response to interleukin-4 (GO:0071353), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL4 | Encodes interleukin-4 cytokine | Ligand initiating the response; produced by cancer cells and fibroblasts |
| IL4R | IL-4 receptor alpha chain | Core receptor subunit; target for blocking IL-4 signaling |
| IL13RA1 | Type II receptor subunit | Mediates IL-4 and IL-13 signaling in non-hematopoietic cells |
| JAK1 | Janus kinase 1 | Phosphorylates STAT6 downstream of IL-4R |
| JAK3 | Janus kinase 3 | Associates with gamma-c chain in type I receptor |
| STAT6 | Signal transducer and activator of transcription 6 | Master transcription factor for IL-4 responses |
| IRS1 | Insulin receptor substrate 1 | Links IL-4R to PI3K-AKT signaling |
| IRS2 | Insulin receptor substrate 2 | Alternative IRS adaptor for IL-4 signaling |
| GATA3 | Transcription factor | Induced by IL-4; drives Th2 differentiation |
| SOCS1 | Suppressor of cytokine signaling 1 | Negative feedback regulator of IL-4 signaling |
| CCL26 | Eotaxin-3 chemokine | IL-4-induced chemokine in fibroblasts and epithelial cells |
| PADI4 | Peptidyl arginine deiminase 4 | Involved in IL-4-driven macrophage extracellular traps in HCC |
| ARHGDIG | Rho GDP dissociation inhibitor gamma | Linked to IL-4/PADI4 axis in hepatocellular carcinoma |
| IL13 | Interleukin-13 | Shares type II receptor with IL-4; contributes to skin barrier dysfunction |
| IL22 | Interleukin-22 | Distinct cytokine with roles in atopic dermatitis |
| FCER2 | Low-affinity IgE receptor (CD23) | IL-4-induced marker on B cells |
| CD40LG | CD40 ligand | Cooperates with IL-4 in B-cell class switching |
How Is cellular response to interleukin-4 Regulated?
The cellular response to IL-4 is tightly regulated at multiple levels. SOCS proteins, particularly SOCS1 and SOCS3, are induced by IL-4 and act as negative feedback inhibitors of JAK-STAT6 signaling. Receptor internalization and degradation also attenuate the response. In cancer, sustained IL-4 signaling in the tumor microenvironment can be driven by cancer cell-derived IL-4 and bone marrow niches, overriding normal feedback controls. Additionally, IL-4 and IL-13 can cooperate or compete for receptor complexes, fine-tuning the response in different cell types.
cellular response to interleukin-4 and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL4 | Ovarian cancer immunotherapy resistance | IL4 knockout ovarian cancer cell lines |
| IL4R | Atopic dermatitis | IL4R knockout keratinocytes or fibroblasts |
| STAT6 | Th2-driven inflammation | STAT6 knockout T cells or macrophages |
| PADI4 | Hepatocellular carcinoma drug resistance | PADI4 knockout HCC cells |
| IL13 | Skin barrier dysfunction | IL13 overexpression in skin models |
Cancer Immunotherapy Resistance
Ovarian cancer-derived IL-4 promotes immunotherapy resistance by reprogramming the tumor microenvironment. An IL-4 signaling axis in bone marrow drives pro-tumorigenic myelopoiesis, supporting tumor progression. In hepatocellular carcinoma, IL-4 contributes to drug resistance through macrophage extracellular traps via the ARHGDIG/IL4/PADI4 axis.
Atopic Dermatitis and Skin Barrier Dysfunction
IL-4 and IL-13 impair skin barrier function and promote T-cell recruitment in atopic dermatitis. Dermal fibroblasts respond to IL-4 and IL-13 by producing chemokines that recruit T cells, amplifying inflammation. Nasal mucosal fibroblasts can also produce IL-4 to induce Th2 responses, linking IL-4 to allergic rhinitis.
Host Defense and Infection
IL-4 modulates host defense against intracellular pathogens such as Listeria monocytogenes, where it can suppress protective Th1 responses. This highlights the dual role of IL-4 in immunity and pathogenesis.
From cellular response to interleukin-4-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL-4 drive immunotherapy resistance? | IL4 knockout cancer cell lines |
| What is the role of STAT6 in Th2 differentiation? | STAT6 knockout primary T cells |
| How does IL-4 affect fibroblast chemokine production? | IL4R knockout dermal fibroblasts |
| Does PADI4 mediate IL-4-induced drug resistance? | PADI4 knockout HCC cells |
| What is the impact of IL-4 on bone marrow myelopoiesis? | IL4 knockout bone marrow chimeras |
| Can IL-4 receptor blockade reverse atopic dermatitis? | IL4R point-mutation knock-in mice |
How to Study the cellular response to interleukin-4 Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify IL-4-induced transcriptional programs |
| Phosphoproteomics | Phosphorylation events | Map JAK-STAT6 signaling dynamics |
| Flow cytometry | Surface markers and differentiation | Measure CD23 induction and Th2 polarization |
| Immunofluorescence | Protein localization | Visualize STAT6 nuclear translocation |
| CRISPR knockout screens | Gene essentiality | Discover regulators of IL-4 response |
| ELISA | Cytokine secretion | Quantify IL-4, IL-5, IL-13 production |
| Western blot | Protein expression and phosphorylation | Validate STAT6 activation |
Transcriptomic Profiling
RNA-seq is widely used to measure gene expression changes following IL-4 stimulation, identifying STAT6 target genes and cell-type-specific responses. This method reveals the transcriptional program underlying GO:0071353.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics can quantify phosphorylation events downstream of IL-4 receptor activation, including JAK and STAT6 phosphorylation. This provides a global view of signaling dynamics.
Flow Cytometry and Imaging
Flow cytometry is used to measure surface markers such as CD23 (FCER2) induced by IL-4, and to assess Th2 differentiation. Imaging can visualize STAT6 nuclear translocation and fibroblast activation.
CRISPR Screens
Genome-wide CRISPR knockout screens can identify genes required for cellular responses to IL-4, such as regulators of STAT6 activation or IL-4 receptor trafficking. These screens are powerful for discovering novel pathway components.
How CRISPR Can Be Used to Study GO:0071353 cellular response to interleukin-4
Knockout
CRISPR knockout of IL4, IL4R, or STAT6 is used to abolish the cellular response to IL-4 and test its role in disease models. For example, IL4 knockout in ovarian cancer cells reduces immunotherapy resistance.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to disable specific phosphorylation sites in IL-4R or STAT6, allowing precise dissection of signaling nodes.
Knock-in
Knock-in of tagged IL-4R or STAT6 enables tracking of receptor trafficking and transcription factor dynamics in live cells. This is useful for understanding spatiotemporal aspects of GO:0071353.
Overexpression
Overexpression of IL-4 or IL-13 in cell lines or mouse models can drive Th2 inflammation and tumor progression, mimicking pathological states. This approach helps identify downstream effectors.
How EDITGENE Supports cellular response to interleukin-4 Research
Researchers studying cellular response to interleukin-4-related genes often need to determine whether a candidate gene is causally involved in IL-4 signaling or is merely a bystander. CRISPR-based models provide the gold standard for establishing causality, and EDITGENE offers a comprehensive suite of services to accelerate this work.
Contact EDITGENE today to design your custom CRISPR model for cellular response to interleukin-4 research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| IL24 Knockout HEK293 Cell Line | EDJ-KQ133 | Human | 11009 | Details Get a Quote |
| LEF1 Knockout HEK293 Cell Line | EDJ-KQ312 | Human | 51176 | Details Get a Quote |
| TCF7 Knockout HEK293 Cell Line | EDJ-KQ338 | Human | 6932 | Details Get a Quote |
| IL20RA Knockout HEK293 Cell Line | EDJ-KQ486 | Human | 53832 | Details Get a Quote |
| IL20RB Knockout HEK293 Cell Line | EDJ-KQ487 | Human | 53833 | Details Get a Quote |
| XBP1 Knockout HEK293 Cell Line | EDJ-KQ1004 | Human | 7494 | Details Get a Quote |
| GATA3 Knockout HEK293 Cell Line | EDJ-KQ1017 | Human | 2625 | Details Get a Quote |
| SHPK Knockout HEK293 Cell Line | EDJ-KQ2813 | Human | 23729 | Details Get a Quote |
| DCSTAMP Knockout HEK293 Cell Line | EDJ-KQ3789 | Human | 81501 | Details Get a Quote |
| ADAMTS13 Knockout HEK293 Cell Line | EDJ-KQ7280 | Human | 11093 | Details Get a Quote |
| IL22RA1 Knockout HEK293 Cell Line | EDJ-KQ13091 | Human | 58985 | Details Get a Quote |
| RUFY4 Knockout HEK293 Cell Line | EDJ-KQ15149 | Human | 285180 | Details Get a Quote |
| TCF7 Knockout A-549 Cell Line | EDJ-KQ17973 | Human | 6932 | Details Get a Quote |
| XBP1 Knockout A-549 Cell Line | EDJ-KQ20054 | Human | 7494 | Details Get a Quote |
| XBP1 Knockout HCT 116 Cell Line | EDJ-KQ20055 | Human | 7494 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About cellular response to interleukin-4
What is GO:0071353?
GO:0071353 is the Gene Ontology term for cellular response to interleukin-4, defined as any process that results in a change in state or activity of a cell as a result of an interleukin-4 stimulus.
What genes are involved in cellular response to interleukin-4?
Key genes include IL4, IL4R, IL13RA1, JAK1, JAK3, STAT6, IRS1, IRS2, GATA3, and SOCS1.
What diseases are associated with IL-4 signaling?
IL-4 signaling is linked to atopic dermatitis, asthma, allergy, ovarian cancer immunotherapy resistance, and hepatocellular carcinoma drug resistance.
How does IL-4 activate cells?
IL-4 binds to type I or type II receptors, activating JAK kinases that phosphorylate STAT6, which then translocates to the nucleus to turn on target genes.
What is the role of STAT6 in IL-4 response?
STAT6 is the master transcription factor downstream of IL-4 receptor activation; it drives Th2 differentiation and alternative macrophage activation.
How can I study cellular response to interleukin-4 using CRISPR?
CRISPR knockout, knock-in, and overexpression models can be used to test the causal role of specific genes in IL-4 signaling.
What cell types respond to IL-4?
T cells, B cells, macrophages, fibroblasts, epithelial cells, and cancer cells all respond to IL-4.
Is IL-4 involved in cancer?
Yes, IL-4 in the tumor microenvironment promotes immunotherapy resistance and pro-tumorigenic myelopoiesis.
What is the difference between IL-4 and IL-13 signaling?
IL-4 and IL-13 share the type II receptor (IL-4Ralpha/IL-13Ralpha1) but have distinct roles in skin barrier dysfunction and inflammation.
How does IL-4 affect fibroblasts?
IL-4 and IL-13 stimulate dermal fibroblasts to produce chemokines that recruit T cells, contributing to atopic dermatitis.
Conclusion
The cellular response to interleukin-4 (GO:0071353) is a fundamental biological process that shapes immune responses, tissue remodeling, and cancer progression. Its dysregulation is implicated in allergic diseases and immunotherapy resistance, making it a key area of research. CRISPR-based models are indispensable for dissecting the causal roles of IL-4 pathway genes, and EDITGENE provides the tools and expertise to accelerate these discoveries.
References
- 1. Mollaoglu G et al.. 2024. Ovarian cancer-derived IL-4 promotes immunotherapy resistance.. Cell 187(26):7492-7510.e22 PMID: 39481380
- 2. LaMarche NM et al.. 2024. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.. Nature 625(7993):166-174 PMID: 38057662
- 3. Junttila IS. 2018. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes.. Front Immunol 9:888 PMID: 29930549
- 4. Huang X et al.. 2024. Sorafenib-induced macrophage extracellular traps via ARHGDIG/IL4/PADI4 axis confer drug resistance through inhibiting ferroptosis in hepatocellular carcinoma.. Biol Direct 19(1):110 PMID: 39529192
- 5. D'Avino P et al.. 2026. Distinct Roles of IL-4, IL-13, and IL-22 in Human Skin Barrier Dysfunction and Atopic Dermatitis.. Allergy 81(2):480-497 PMID: 40985485
- 6. Kaufmann SH et al.. 1997. Interleukin-4 and listeriosis.. Immunol Rev 158:95-105 PMID: 9314077
- 7. Numata T et al.. 2026. Dermal fibroblasts respond to IL-4 and IL-13 and promote T cell recruitment in atopic dermatitis.. J Clin Invest 136(5) PMID: 41569693
- 8. Zeng X et al.. 2024. Nasal mucosal fibroblasts produce IL-4 to induce Th2 response.. Innate Immun 30(2-4):55-65 PMID: 38725177
